Beximco Launches World’s First Molnupiravir Generic
Generic Version Of MSD’s Oral Therapy For COVID-19 To Be Marketed As Emorivir
Bangladesh’s Beximco has launched the world’s first molnupiravir generic, to be marketed as Emorivir, following an emergency use authorization by the local regulator. The company told Generics Bulletin it was able to manufacture and sell its version of the MSD oral COVID-19 treatment thanks to the WTO’s TRIPS waiver for less economically developed countries.
You may also be interested in...
The EU regulator says it is taking the emergency use route for molnupiravir because of the worrying rise in coronavirus infections and deaths.
The European Medicines Agency is considering making a rapid recommendation on MSD’s molnupiravir in order to speed access to the potential ‘game changer’ COVID-19 pill.
The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.